Interleukin-1 Inhibitors Show Excellent Retention Rates in sJIA Patients
News
Sobi‘s Kineret (anakinra) and Novartis‘ Ilaris (canakinumab), two interleukin-1 inhibitors that have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of systemic onset juvenile arthritis (sJIA), ... Read more